Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Growth, recognition, results—and an important partnership
Posted on January 17th, 2019 by admin in Pharma R&D
Here at Sigilon Therapeutics, we have had a very exciting period of growth recently, including receiving an Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency, adding two new members to our leadership team and initiating a collaboration with Eli Lilly in type 1 diabetes. We are very pleased that Eli Lilly recognized us as a leader in encapsulation and engineering cells to reach a functional cure for type 1 diabetes. Lilly has been a global leader in diabetes care for over 90 years, and we are already benefiting greatly from their expertise in this space.
We think the milestones we’ve reached have shown that our work in creating Shielded Living Therapeutics is really resonating with the community, and our preclinical results so far have been very promising. Also, a huge part of our success is our growing team — their passion and ingenuity are at the core of all our accomplishments.
Driving innovation with research solutions
Being a part of the Hive has also helped to fuel our success. Elsevier solutions have enabled our team to remain creative and efficient in our approach as we continue to advance our platform and move our lead programs toward the clinic. While the team takes full advantage of all the available tools, ScienceDirect has proven to be most instrumental. With widespread access to journals across multiple disciplines, many of our scientists routinely start with this solution as a means to investigate the question or topic at hand
What’s on the horizon for Sigilon Therapeutics in 2019
One of the biggest milestones we anticipate for 2019 is the start of clinical trials for our lead candidate, SIG-001, in hemophilia A. We also plan to continue growing our team and advancing our promising pipeline in type 1 diabetes and lysosomal storage disorders. We’re very eager to see what Sigilon can accomplish in the New Year!
In-Vivo Biology Lead at Sigilon Therapeutics, Inc.
Janet (Jinghan) Huang is an In-Vivo Biology Lead at Sigilon Therapeutics, Inc. since August 2017.
Connect with Janet Huang via LinkedIn
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
- Emulating start-up success with purpose-built data tools
- Rapid Growth and Promising Partnerships
- Drug Companies Collaborate to Take on the Opioid Crisis
- Emerging Oncology Drugs in Pharma R&D Pipeline
- HIV Treatment: Dual Therapies and Dueling Companies